Stage 1 non-small cell lung cancer

Stage 1 NSCLC means the cancer is limited to the lung area where it began, without evidence of spread to nearby lymph nodes or distant organs on the staging assessment. The stage is refined by tumour size, location, lymph-node findings, scans, and tissue results. NSCLC includes several tumour types, so the name alone does not determine the plan.

A scan may suggest a tumour, but pathology confirms the diagnosis. Your team may also consider lung function, heart health, other conditions, and how much lung tissue could be safely treated.

For a person who can have surgery, removal of the affected lung section may be recommended, sometimes with nearby lymph-node sampling. Lung Lobectomy removes a lobe and is one surgical option; smaller resections may suit selected tumours. When surgery is not suitable, Stereotactic Body Radiotherapy can deliver focused radiation to a defined lung target.

Tissue testing may look for features that affect later treatment decisions. Targeted Therapy and Immunotherapy are not automatically needed for every stage 1 tumour; their role depends on pathology, biomarkers, recurrence risk, and the multidisciplinary plan. Ask how follow-up scans and breathing rehabilitation will be organised.

Contact your care team promptly for new or worsening breathlessness, chest pain, fever, coughing blood, or a sudden drop in activity after diagnosis or treatment. Seek emergency help for severe breathing difficulty, fainting, confusion, blue lips, or heavy bleeding.

Before treatment, report infections and changes in medicines. After surgery or radiotherapy, ask which wound, breathing, fever, or pain changes need same-day advice; the threshold can differ with the treatment used.

Ask: What is the exact stage and tumour type? Were lymph nodes assessed? Is surgery suitable for my lung function? Why might focused radiotherapy be considered? Are biomarker tests relevant? What are the aims, side effects, and follow-up schedule for each option?